Expression of CCR1 and CCR2 on the cell surface of the PB lymphocytes, CD19+CD5+, CD19+CD5−, and CD19− (designated as T-NK lymphocytes), and PB monocytes was determined in CLL patients in all groups. This evidence concerns the gene CD5 and B-cell chronic lymphocytic leukemia.